GlycoNex (4168) - Net Assets

Latest as of September 2025: NT$1.01 Billion TWD ≈ $31.84 Million USD

Based on the latest financial reports, GlycoNex (4168) has net assets worth NT$1.01 Billion TWD (≈ $31.84 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.55 Billion ≈ $48.92 Million USD) and total liabilities (NT$542.22 Million ≈ $17.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GlycoNex tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	NT$1.01 Billion
% of Total Assets	65.08%
Annual Growth Rate	-7.75%
5-Year Change	-32.03%
10-Year Change	N/A
Growth Volatility	12.81

GlycoNex - Net Assets Trend (2017–2024)

This chart illustrates how GlycoNex's net assets have evolved over time, based on quarterly financial data. See GlycoNex defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for GlycoNex (2017–2024)

The table below shows the annual net assets of GlycoNex from 2017 to 2024. For live valuation and market cap data, see market cap of GlycoNex.

Year	Net Assets	Change
2024-12-31	NT$1.05 Billion ≈ $32.97 Million	-18.01%
2023-12-31	NT$1.28 Billion ≈ $40.21 Million	-11.70%
2022-12-31	NT$1.45 Billion ≈ $45.54 Million	+6.38%
2021-12-31	NT$1.36 Billion ≈ $42.81 Million	-11.73%
2020-12-31	NT$1.54 Billion ≈ $48.51 Million	+18.35%
2019-12-31	NT$1.30 Billion ≈ $40.98 Million	-15.11%
2018-12-31	NT$1.53 Billion ≈ $48.28 Million	-16.77%
2017-12-31	NT$1.84 Billion ≈ $58.01 Million	--

Equity Component Analysis

This analysis shows how different components contribute to GlycoNex's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2572700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	NT$1.28 Billion	121.92%
Total Equity	NT$1.05 Billion	100.00%

GlycoNex Competitors by Market Cap

The table below lists competitors of GlycoNex ranked by their market capitalization.

Company	Market Cap
Lavras Gold Corp V:LGC	$88.61 Million
Fluent Inc NASDAQ:FLNT	$88.61 Million
CAB Cakaran Corporation Bhd KLSE:7174	$88.66 Million
Delta Djakarta Tbk JK:DLTA	$88.67 Million
OFX Group Ltd AU:OFX	$88.55 Million
Aditya Birla Money Limited NSE:BIRLAMONEY	$88.53 Million
Rama Steel Tubes Limited NSE:RAMASTEEL	$88.47 Million
Geopacific Resources Ltd AU:GPR	$88.46 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GlycoNex's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,276,415,000 to 1,046,474,000, a change of -229,941,000 (-18.0%).
Net loss of 229,705,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	NT$-229.71 Million	-21.95%
Other Changes	NT$-236.00K	-0.02%
Total Change	NT$-	-18.01%

Book Value vs Market Value Analysis

This analysis compares GlycoNex's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.63x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 1.04x to 2.63x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	NT$24.37	NT$25.40	x
2018-12-31	NT$20.23	NT$25.40	x
2019-12-31	NT$17.14	NT$25.40	x
2020-12-31	NT$17.22	NT$25.40	x
2021-12-31	NT$14.02	NT$25.40	x
2022-12-31	NT$14.54	NT$25.40	x
2023-12-31	NT$11.84	NT$25.40	x
2024-12-31	NT$9.65	NT$25.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GlycoNex utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -21.95%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1562.51%
• Asset Turnover: 0.01x
• Equity Multiplier: 1.26x
Recent ROE (-21.95%) is below the historical average (-15.24%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	-7.85%	-22805.68%	0.00x	1.01x	NT$-328.71 Million
2018	-20.68%	-34227.11%	0.00x	1.02x	NT$-470.19 Million
2019	-19.00%	-33682.15%	0.00x	1.02x	NT$-377.31 Million
2020	-10.57%	-36082.26%	0.00x	1.02x	NT$-316.69 Million
2021	-12.69%	-3150.56%	0.00x	1.03x	NT$-308.39 Million
2022	-15.21%	-730.67%	0.02x	1.19x	NT$-364.38 Million
2023	-13.97%	-7016.60%	0.00x	1.22x	NT$-306.00 Million
2024	-21.95%	-1562.51%	0.01x	1.26x	NT$-334.35 Million

Industry Comparison

This section compares GlycoNex's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,605,275,000
Average return on equity (ROE) among peers: 6.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GlycoNex (4168)	NT$1.01 Billion	-7.85%	0.54x	$88.59 Million
Apex Biotechnology Corp (1733)	$1.75 Billion	11.53%	0.52x	$92.11 Million
Sinphar Pharmaceutical Co Ltd (1734)	$1.32 Billion	9.26%	0.78x	$190.85 Million
Panion & BF Biotech Inc (1760)	$1.93 Billion	5.40%	0.53x	$161.80 Million
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)	$2.50 Billion	21.29%	0.26x	$85.54 Million
SYN-Tech Chem & Pharm Co Ltd (1777)	$969.06 Million	16.12%	0.26x	$101.71 Million
Level Biotechnology (3118)	$542.40 Million	10.78%	0.50x	$31.95 Million
GenMont Biotech Inc (3164)	$737.87 Million	20.00%	0.85x	$44.44 Million
Medigen Biotechnology (3176)	$3.46 Billion	-15.61%	0.30x	$146.59 Million
Sagittarius Life Science (3205)	$588.38 Million	-12.60%	0.26x	$112.36 Million
Genovate Biotechnology Co Ltd (4130)	$2.25 Billion	1.74%	0.18x	$112.45 Million

About GlycoNex

TWO:4168 Taiwan Biotechnology

Market Cap

$88.59 Million

NT$2.81 Billion TWD

Market Cap Rank

#19754 Global

#1157 in Taiwan

Share Price

NT$25.40

Change (1 day)

+1.20%

52-Week Range

NT$20.80 - NT$30.45

All Time High

NT$67.99